BIOLARGO INC.

BioLargo reported adjusted earnings of -$0.01 per share for Q2 2026, in line with expectations, while revenue of $1.25 million missed the $1.29 million forecast by 3.1%. The stock fell temporarily by up to 4.8% and was last quoted at around $0.099. Management described the quarter as a stabilization after the Pooph exit, pointed to growth in the engineering division and outlined plans such as relaunching the consumer goods business, as well as progress at Clyra, on PFAS projects and in battery technology, but still sees financial weakness and liquidity pressure. » More on de.investing.com

Biolargo released results for the quarter ended March 31, 2026, recording a 66.06% decline in revenue compared with the same period last year. Revenue fell from $3.3 million to $1.1 million. » More on finanzen.net

BioLargo reported total revenue of $7.8 million for 2025 and a net loss of $15.2 million. The services business doubled to $2.0 million, cash stood at $3.9 million, and the termination of the Pooph license led to significant revenue losses. The stock fell 5.32% pre-market and was trading near its 52-week low; management plans to focus on commercialization in Clyra Medical and AEC Water Treatment in 2026. EPS estimates for 2026 are -$0.01. » More on de.investing.com